Targeted Therapy Effective for Head and Neck Cancer Patients

Data from a phase II clinical trial presented at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, showed the investigational therapeutic tipifarnib yielded durable objective responses in patients with recurrent and metastatic head and neck squamous cell carcinoma harboring HRAS gene mutations.